Last checked at 2 Jul 2008 07:30
| For Immediate Release | 2 July 2008 |
ImmuPharma PLC
Long term toxicology studies confirmed the safety of LupuzorTM
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces today LupuzorTM its treatment for Lupus, a chronic, life-threatening autoimmune disease, completed the first leg of the mandatory long term toxicology study package. International regulations require two long term toxicology studies (6 and 9 months) for drug products intended to be use chronically. ImmuPharma reports that the first study has been completed and that there was no clinical or laboratory findings suggesting any safety issues. Further, an interim analysis of the second study supported these findings. These studies were requirements from The FDA (Food and Drug Administration) in the US prior to initiating ImmuPharma's Phase III programme.
For further information please contact:
| ImmuPharma PLC: | |
| Dimitri Dimitriou, Chief Executive Officer | +44 20 7152 4080 |
| Dr Robert Zimmer, President & Chief Scientific Officer | + 33 389 32 76 50 |
| Richard Warr, Chairman | +44 20 7152 4080 |
| Buchanan Communications | + 44 20 7466 5000 |
| Lisa Baderoon | |
| Rebecca Skye Dietrich | |
| Panmure Gordon & Co | |
| Andrew Burnett | +44 151 243 0963 |
For further company information, visit www.immupharma.com